BRIEF published on 12/20/2024 at 07:05, 1 day 12 hours ago Innate Pharma at the 43rd JP Morgan Healthcare Conference Investors Immunotherapy Innate Pharma JP Morgan Conference Live Presentation
PRESS RELEASE published on 12/20/2024 at 07:00, 1 day 12 hours ago Inside Information / Other news releases Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference with CEO Jonathan Dickinson and other executives presenting. Company focuses on developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients J.P. Morgan Healthcare Conference
BRIEF published on 12/06/2024 at 07:05, 15 days 12 hours ago Innate Pharma: Investment of 7.9 million dollars for IPH6501 Investment Clinical Trial Innate Pharma IPH6501 Follicular Lymphoma
BRIEF published on 11/20/2024 at 07:05, 1 month 1 day ago Innate Pharma unveils its financial calendar for 2025 Annual Results Innate Pharma Financial Calendar 2025 Assemblies And Publications Euronext And Nasdaq Contribution
PRESS RELEASE published on 11/20/2024 at 07:00, 1 month 1 day ago Inside Information / Other news releases Innate Pharma releases its 2025 financial calendar including key publication dates for financial statements and shareholder meetings Financial Statements Investors Financial Calendar 2025 Innate Pharma
BRIEF published on 11/08/2024 at 07:05, 1 month 13 days ago Innate Pharma presents its innovations in oncology at SITC 2024 Immunotherapy Innate Pharma SITC 2024 NK Cell Engage Antibody-drug Conjugate
PRESS RELEASE published on 11/08/2024 at 07:00, 1 month 13 days ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
BRIEF published on 06/17/2024 at 07:05, 6 months 4 days ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 6 months 4 days ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 6 months 24 days ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
Published on 12/21/2024 at 01:30, 17 hours 41 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 41 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 6 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 41 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 20 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 26 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 6 hours 53 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
